The Capital Engine
The first rail of the Global Mogul ecosystem — and the most disciplined capital in Latin America. Before the platform. Before the clubs. Before the AI. There is the capital engine.
The Fund is not just a real estate vehicle.
It is the foundation that makes everything else possible.
The Opportunity
Capital is constrained. Assets are undervalued. The institutions haven't arrived yet. We provide disciplined capital upstream in the capital stack — before the market reprices.
Local developers need capital they cannot access through traditional lenders. Global Mogul provides it — at terms that create structural advantage for our investors and unlock deals others simply cannot reach.
The best hospitality assets in Cartagena, Medellín, and Bogotá trade at a fraction of what comparable assets command in Miami, Lisbon, or Dubai. The arbitrage is wide open. The window will not stay that way.
We see the opportunity before anyone else prices it. We position upstream — before the market reprices, before the capital floods in, before the window closes. That is the only time to act.
We are not waiting for the market to agree with us.
We move before it does.
The Structure
SEC-regulated. Offshore-optimized. Colombian-deployed. Every layer of the structure exists for one reason — to protect capital on the downside and compound returns on the upside.
Every layer of the structure has one purpose.
Protect capital. Compound returns.
The Advantage
We are not passive investors waiting for someone else to source the deal. We build the relationships, underwrite with AI, and deploy before institutional capital even knows the asset exists.
| Feature | Traditional LatAm Fund | ● Global Mogul Fund |
|---|---|---|
| Deal sourcing | Broker-dependent. Open market. | Direct developer relationships. Off-market. |
| Underwriting | Manual. Slow. Analyst-dependent. | AI-powered. Proprietary LatAm data. |
| Capital stack position | Mid or junior. High exposure. | First priority. Asset-backed protection. |
| Platform integration | None. Standalone fund only. | Fund feeds Platform, Clubs, and AI layer. |
| Investor access | Institutional only. High minimums. | Accredited investors. Reg A opens 2027. |
| Data advantage | No proprietary data. Generic analysis. | Every deal builds a proprietary LatAm dataset. |
| Liquidity path | Lock-up 5–10 years. No secondary market. | Secondary market via Mogul Exchange (2027). |
The collateral is real. The yield is real.
The structure protects on the downside and compounds on the upside.
Investor Benefits
This is infrastructure pricing. It will not remain available at this stage. Every tranche that closes permanently increases the floor. Founding investors enter before the wider market arrives.
Asset-backed exposure before the platform scales.
Your capital is deployed into real, income-producing assets in Latin America — secured by collateral, not speculation. You earn yield from the first deployment, not from future promises.
Founding allocation at $4M pre-money.
You are entering at the lowest valuation this company will ever have. Every subsequent round closes at a higher price. The founding window does not reopen. Infrastructure pricing ends when Tranche I fills.
Direct line to the founding team.
Founding investors are not ticket numbers. You get direct access to the leadership team, quarterly updates, first look at new deals, and a seat at the table as the ecosystem is built.
SAFE discount on future rounds.
Every founding package includes a SAFE discount ranging from 2% to 15% depending on investment level. Your position in future rounds is protected and discounted before the public ever gets access.
First entry into the ecosystem before Reg A launches.
When Reg A opens in 2027, millions of retail investors will have access for the first time. Founding investors will already hold a position built at infrastructure pricing — years ahead of the crowd.
This is not a pitch. It is an allocation.
The founding window is open. It will not reopen.
Who This Is For
This is not a passive vehicle for patient capital. This is a founding allocation for investors who understand that the best entry points are the ones most people never see.
Profile 01 · Individual Investor
You have capital working in stocks, real estate, or private deals. You are looking for something asymmetric — real yield, real assets, and a position in a category that does not yet exist in most portfolios.
Profile 02 · Family Office / HNW
You manage capital for yourself or others. You have seen what happens when a new category gets infrastructure built beneath it. You are here because Latin America is a decade behind where it should be — and you know what that means.
You need liquidity in under 12 months · You are looking for a guaranteed return · You are not an accredited investor · You want a passive vehicle with no relationship to the team · You are not ready to move now
We are seeking only 10 to 20 strategic investors.
If this is for you, the window is open right now.
Investor Benefits
Built for investors who want returns with status, access, and belonging.
The best investments do not only grow wealth.
They expand freedom, access, and belonging.
It helps secure the first nodes, the first relationships, the first data, and the first layer of real world proof inside the Global Mogul system.
The fund is where disciplined investors can enter early, gain asset backed exposure, and take position before broader access and broader repricing arrive.
This is where current opportunity meets future advantage.
This website and related materials are intended solely for informational purposes and do not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offer to invest will be made only through official offering documents and only to individuals who qualify as accredited investors under SEC Regulation D, Rule 506(c). All investments involve risk, including the possible loss of principal. Past performance is not indicative of future results. Prospective investors should consult with their financial and legal advisors before making any investment decisions.
This website contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this website, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: our ability to raise sufficient capital to execute our business plan; expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidate or any other products we may acquire or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable on a sustained basis; expectations or ability to enter into marketing and other partnership agreements; expectations or ability to enter into product acquisition and in-licensing transactions; expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidates; acceptance of our products by doctors, patients or payors; our ability to compete against other companies and research institutions; our ability to secure adequate protection for our intellectual property; our ability to attract and retain key personnel; availability of reimbursement for our products; expected losses; and expectations for future capital requirements. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise thereafter, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.